parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in podocytes	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 39	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 12764

APBB2 in dopamine neurons, braak-0.11 (p 0.779) → -0.23 (p 0.551)receipt 12772
APBB2 in oligodendrocytes, braak+0.30 (p 0.436) → -0.11 (p 0.787)receipt 12771

receipt 12772: APBB2 in dopamine neurons, braak

power: full sample -0.29 (p 0.235, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.31 (p 0.218, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.30 (p 0.228, n 18). could be the mix.
skeptic: leave-one-out range -0.46 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.235, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for APBB2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12771: APBB2 in oligodendrocytes, braak

power: full sample +0.01 (p 0.956, n 18), 95% CI -0.46 to +0.48. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.01 (p 0.976, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.07 (p 0.774, n 18). could be the mix.
skeptic: leave-one-out range -0.13 to +0.12, sign flips 6; without severely affected donors +0.01 (p 0.956, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for APBB2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts